dc.contributor.author | Barratt-Due, Andreas | |
dc.contributor.author | Fløisand, Yngvar | |
dc.contributor.author | Lang, Hilde Elisabeth | |
dc.contributor.author | Kvam, Ann Kristin | |
dc.contributor.author | Holme, Pål Andre | |
dc.contributor.author | Bergseth, Grete | |
dc.contributor.author | Tjønnfjord, Geir Erland | |
dc.contributor.author | Mollnes, Tom Eirik | |
dc.date.accessioned | 2017-03-14T12:34:25Z | |
dc.date.available | 2017-03-14T12:34:25Z | |
dc.date.issued | 2016-04-22 | |
dc.description.abstract | Catastrophic antiphospholipid syndrome is associated with excessive complement activation explaining the clinical efficacy of complement inhibitory treatment. | en_US |
dc.description | Full text source is available at: https://doi.org/10.1093/rheumatology/kew040 | en_US |
dc.identifier.citation | Barratt-Due A, Fløisand Y, Lang HEL, Kvam AK, Holme PA, Bergseth G, Tjønnfjord GE, Mollnes TE. Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. Rheumatology. 2016 | en_US |
dc.identifier.cristinID | FRIDAID 1439398 | |
dc.identifier.doi | 10.1093/rheumatology/kew040 | |
dc.identifier.issn | 1462-0324 | |
dc.identifier.issn | 1462-0332 | |
dc.identifier.uri | https://hdl.handle.net/10037/10654 | |
dc.language.iso | eng | en_US |
dc.publisher | Oxford University Press | en_US |
dc.relation.ispartofseries | Volume 55, Issue 7 | en_US |
dc.relation.journal | Rheumatology | |
dc.relation.projectID | Stiftelsen Kristian Gerhard Jebsen: SKJG-MED-012 | en_US |
dc.relation.projectID | info:eu-repo/grantAgreement/RCN/SFF223255/Norway/CentreofMolecularInflammationResearch/CEMIR | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.subject | VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Rheumatology: 759 | en_US |
dc.subject | CAPS | en_US |
dc.subject | Catastrophic antiphospholipid syndrome | en_US |
dc.subject | clinical efficacy | en_US |
dc.subject | treatment | en_US |
dc.subject | APS | en_US |
dc.subject | Eculizumab | en_US |
dc.subject | pathophysiology | en_US |
dc.title | Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome. | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |